Drugs / PEGMISPOTIDE
PEGMISPOTIDE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05084261 | Nov 2021 → Nov 2022 | ulcerative colitis | Adiso Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05103878 | Jun → Nov 2020 | — | Bacainn Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGMISPOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314863 ↗ |
| Known as | ADS051 | “ADS051 is a small-molecule inhibiting neutrophil migration and activation, which are potentially important therapeutic targets in UC.” PMID 39588987 ↗ Nov 2024 |
| Known as | BT051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05103878 ↗ |
| Known as | Pegmispotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314863 ↗ |
| Action | Inhibit | “small-molecule inhibiting neutrophil migration and activation” PMID 39588987 ↗ Nov 2024 |
| Modality | Small molecule | “ADS051 is a novel, oral, gut-restricted small molecule” PMID 39787364 ↗ Dec 2024 |
| Route | Oral | “administered orally once daily for 28 days” PMID 39787364 ↗ Dec 2024 |